These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22302226)

  • 21. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 22. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.
    Dent R; Clemons M
    Cancer Treat Rev; 2006 Apr; 32(2):144-8. PubMed ID: 16517084
    [No Abstract]   [Full Text] [Related]  

  • 23. Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy.
    Bellati F; Napoletano C; Ruscito I; Liberati M; Panici PB; Nuti M
    J Clin Oncol; 2010 Jul; 28(21):e369-70; author reply e371. PubMed ID: 20479394
    [No Abstract]   [Full Text] [Related]  

  • 24. Economic evaluation and decision making: reimbursing trastuzumab in early-stage breast cancer.
    Simoens S
    Pharmacoeconomics; 2007; 25(3):181-5. PubMed ID: 17335304
    [No Abstract]   [Full Text] [Related]  

  • 25. "Build quality in"--HER2 testing in the real world.
    Zujewski JA
    J Natl Cancer Inst; 2002 Jun; 94(11):788-9. PubMed ID: 12048261
    [No Abstract]   [Full Text] [Related]  

  • 26. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia.
    Buendía JA; Vallejos C; Pichón-Rivière A
    Biomedica; 2013; 33(3):411-7. PubMed ID: 24652177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In brief: Phesgo - a fixed-dose combination for HER-2 positive breast cancer.
    Med Lett Drugs Ther; 2021 Mar; 63(1619):e43-e44. PubMed ID: 33755658
    [No Abstract]   [Full Text] [Related]  

  • 28. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
    Burstein HJ; Winer EP
    J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
    [No Abstract]   [Full Text] [Related]  

  • 29. Trastuzumab beyond progression in HER2-positive metastatic breast cancer.
    Al-Naqqash M; Jasim Al-Serarati W; Farooq Kareem T
    Breast J; 2021 Mar; 27(3):297-299. PubMed ID: 33472271
    [No Abstract]   [Full Text] [Related]  

  • 30. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.
    Hedden L; O'Reilly S; Lohrisch C; Chia S; Speers C; Kovacic L; Taylor S; Peacock S
    Oncologist; 2012; 17(2):164-71. PubMed ID: 22302231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
    Wolff AC; Hammond ME; Hayes DF
    J Natl Cancer Inst; 2012 Jun; 104(12):957-8. PubMed ID: 22581974
    [No Abstract]   [Full Text] [Related]  

  • 32. Experts debate value of HER2 testing methods.
    Nelson NJ
    J Natl Cancer Inst; 2000 Feb; 92(4):292-4. PubMed ID: 10675369
    [No Abstract]   [Full Text] [Related]  

  • 33. Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients.
    Bighin C; Pronzato P; Del Mastro L
    Future Oncol; 2013 Jul; 9(7):955-7. PubMed ID: 23837759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: HER2 testing in the real world.
    Vincent-Salomon A; MacGrogan G; Couturier J; Arnould L; Mathoulin-Pélissier S;
    J Natl Cancer Inst; 2003 Apr; 95(8):628; author reply 628-9. PubMed ID: 12697858
    [No Abstract]   [Full Text] [Related]  

  • 35. Trastuzumab faces trials, clinical and otherwise.
    Tuma RS
    J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
    [No Abstract]   [Full Text] [Related]  

  • 36. A systematic review of the economic evaluations of trastuzumab in metastatic breast cancer.
    Petrou P
    Breast J; 2020 Sep; 26(9):1903-1905. PubMed ID: 32383220
    [No Abstract]   [Full Text] [Related]  

  • 37. Trastuzumab therapy for the metastatic patient: does the primary match?
    Leyland-Jones B
    Ann Oncol; 2002 Jul; 13(7):993-4. PubMed ID: 12176776
    [No Abstract]   [Full Text] [Related]  

  • 38. Trastuzumab administration associated with change in HER2 status.
    Dawood S; Resetkova E; Gonzalez-Angulo AM
    Clin Breast Cancer; 2008 Aug; 8(4):366-9. PubMed ID: 18757266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?
    Gujral DM; Lloyd G; Bhattacharyya S
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):446-7. PubMed ID: 23583229
    [No Abstract]   [Full Text] [Related]  

  • 40. [Current status and prospects of antibody drugs-trastuzumab].
    Fujimoto-Ouchi K
    Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):210-4. PubMed ID: 20948156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.